Huons Biopharma Obtains Approval for 50 Units of Botulinum Toxin 'Liztox'

Liztox 50 units (Photo by Huons Biopharma)

[Asia Economy Reporter Kim Ji-hee] The lineup of Huons Biopharma's botulinum toxin 'Liztox' is expanding.

Huons Biopharma, a subsidiary of Huons Global, announced on the 16th that it has obtained domestic approval from the Ministry of Food and Drug Safety for a new manufacturing unit of the botulinum toxin 'Liztox' (export name: HUTOX), the 'Liztox Injection 50 Units'. With this, Liztox now has a total of two manufacturing units, with the previously released 100 units supplemented by the new 50 units. Additionally, approval for 200 units is expected in August.

Since the dosage of botulinum toxin is determined according to the treatment area and scope, appropriate dosages are selected and used based on the needs of medical professionals and patients. Huons Biopharma explained, "We pursued approval for the new dosage to broaden the range of choices available in medical practice."

The 50-unit Liztox is expected to be competitive in the aesthetic field where relatively small amounts are used, while the 200-unit dosage, pending approval in August, is anticipated to enhance competitiveness in therapeutic areas such as post-stroke upper limb spasticity treatment and benign masseter hypertrophy, for which clinical trials are currently underway to add indications.

Kim Young-mok, CEO of Huons Biopharma, stated, "We are pursuing approval for various dosages to meet market demands," adding, "We plan to proactively obtain approval for the 200-unit dosage so that we can immediately enter the market after acquiring indications for therapeutic areas currently in clinical trials, not just the 50-unit dosage."

Meanwhile, Liztox currently holds aesthetic indications such as improvement of glabellar lines and crow's feet. In therapeutic areas, it is awaiting IND approval for Phase 3 clinical trials for post-stroke upper limb spasticity treatment, and Phase 2 clinical trials for benign masseter hypertrophy are also underway. Huons Biopharma plans to accelerate clinical trials for expanding Liztox indications and for a new botulinum toxin 'HU-045', which reduces the development of resistance.

This content was produced with the assistance of AI translation services.